kabutan

Medrx Co.,Ltd.(4586) Summary

4586
TSE Growth
Medrx Co.,Ltd.
115
JPY
-2
(-1.71%)
Dec 5, 12:46 pm JST
0.74
USD
Dec 4, 10:46 pm EST
Result
PTS
outside of trading hours
115.3
Dec 5, 12:46 pm JST
Summary Chart Historical News Financial Result
PER
PBR
3.28
Yield
ー%
Margin Trading Ratio
Stock Price
Dec 5, 2025
Opening Dec 5, 9:00 am
116 JPY 0.74 USD
Previous Close Dec 4
117 JPY 0.75 USD
High Dec 5, 9:00 am
117 JPY 0.75 USD
Low Dec 5, 10:50 am
113 JPY 0.72 USD
Volume
372,200
Trading Value
0.04B JPY 0.28M USD
VWAP
114.88 JPY 0.74 USD
Minimum Trading Value
11,500 JPY 74 USD
Market Cap
6.83B JPY 0.04B USD
Number of Trades
153
Liquidity & Number of Trades
As of Dec 5, 2025
Liquidity
Slightly High
1-Year Average
838
1-Year High Sep 29, 2025
32,058
Margin Trading
Date Short Interest Long Margin Positions Ratio
Nov 28, 2025 0 6,953,500
Nov 21, 2025 0 7,141,800
Nov 14, 2025 300 7,823,200 26077.33
Nov 7, 2025 0 7,919,100
Oct 31, 2025 0 8,129,000
Company Profile
Medrx Co., Ltd. is a drug discovery venture company with strengths in transdermal drug delivery system technologies and microneedle array technology.
Sector
Pharmaceuticals
Medrx Co., Ltd. aims to create new value-added pharmaceuticals through its proprietary transdermal drug delivery system technologies, primarily ILTS and NCTS. These technologies maximize drug efficacy, reduce side effects, and enable drug administration to patients who have difficulty with oral intake. One of the company's main development pipelines, MRX-5LBT for the treatment of post-herpetic neuralgia, received a Complete Response Letter from the FDA in September 2023. Other pipelines include MRX-4TZT for spastic paralysis, MRX-9FLT for central analgesic, and MRX-7MLL for Alzheimer's disease. Additionally, the company is developing microneedle technology, a vaccine delivery device that allows for painless self-administration. Medrx Co., Ltd. is expanding globally through its U.S. subsidiary and is promoting development and commercialization through partnerships with pharmaceutical companies and other entities.